Cargando…

Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

This study was designed to investigate the impact of blood tumor mutational burden (bTMB) on advanced NSCLC in Southwest China. The relationship between the tTMB estimated by next-generation sequencing (NGS) and clinical outcome was retrospectively analyzed in tissue specimens from 21 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Yuhui, Li, Quan, Du, Yaxi, Cai, Jingjing, Chen, Wanlin, Zhao, Guangqiang, Liu, Xing, Li, Hongsheng, Ma, Luyao, Huang, Yunchao, Zhou, Yongchun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160368/ https://www.ncbi.nlm.nih.gov/pubmed/34055609 http://dx.doi.org/10.3389/fonc.2021.640761

Ejemplares similares

Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China
por: Ma, Yuhui, et al.
Publicado: (2020)

Oncogenic Genetic Alterations in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China
por: Ma, Yuhui, et al.
Publicado: (2020)

Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
por: Zhou, Yongchun, et al.
Publicado: (2018)

Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
por: Zhou, Yongchun, et al.
Publicado: (2017)

Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study
por: Lin, Yanping, et al.
Publicado: (2023)

Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China
por: Zhou, Yongchun, et al.
Publicado: (2021)

Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China
por: Ma, Yuhui, et al.
Publicado: (2023)

Mutational characteristics of Chinese Han and ethnic minorities in southwestern China: a propensity score matched analysis
por: Zhou, Yongchun, et al.
Publicado: (2022)

MicroRNA‐195 suppresses the progression of lung adenocarcinoma by directly targeting apelin
por: Zhou, Yongchun, et al.
Publicado: (2019)

Heterogeneity of tumour mutational burden in metastatic NSCLC demonstrated by endobronchial ultrasound sampling
por: Leong, Tracy L., et al.
Publicado: (2023)

Accurate Classification of Non-small Cell Lung Cancer (NSCLC) Pathology and Mapping of EGFR Mutation Spatial Distribution by Ambient Mass Spectrometry Imaging
por: Zhang, Min, et al.
Publicado: (2019)

A Computed Tomography-Derived Radiomics Approach for Predicting Uncommon EGFR Mutation in Patients With NSCLC
por: Chen, Wufei, et al.
Publicado: (2021)

Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC
por: He, Ping, et al.
Publicado: (2023)

GEO Data Mining Identifies OLR1 as a Potential Biomarker in NSCLC Immunotherapy
por: Liu, Bin, et al.
Publicado: (2021)

Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy
por: Li, Jingpei, et al.
Publicado: (2020)

The role of artificial intelligence based on PET/CT radiomics in NSCLC: Disease management, opportunities, and challenges
por: Hu, Qiuyuan, et al.
Publicado: (2023)

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
por: Wang, Peipei, et al.
Publicado: (2021)

Tumor Mutational Burden Associated With Response to Hyperthermic Intraperitoneal Chemotherapy
por: Zeng, Lisi, et al.
Publicado: (2022)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Cai, Boning, et al.
Publicado: (2021)

PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs
por: Yang, Liping, et al.
Publicado: (2022)

Editorial: Emerging Biomarkers for NSCLC: Recent Advances in Diagnosis and Therapy
por: Malapelle, Umberto, et al.
Publicado: (2021)

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report
por: Shen, Qian, et al.
Publicado: (2021)

Prognostic signature of lipid metabolism associated LncRNAs predict prognosis and treatment of lung adenocarcinoma
por: Zhao, Jie, et al.
Publicado: (2022)

Predictive Power of a Radiomic Signature Based on (18)F-FDG PET/CT Images for EGFR Mutational Status in NSCLC
por: Li, Xiaofeng, et al.
Publicado: (2019)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Dong, Wei, et al.
Publicado: (2022)

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview
por: Van De Stadt, Eveline, et al.
Publicado: (2022)

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients
por: Tian, Yanhua, et al.
Publicado: (2020)

Editorial: Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutations
por: Su, Chunxia, et al.
Publicado: (2022)

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
por: Tian, Tian, et al.
Publicado: (2021)

MTA1-TJP1 interaction and its involvement in non-small cell lung cancer metastasis
por: Wang, Wei, et al.
Publicado: (2022)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations
por: Ma, Tiantian, et al.
Publicado: (2022)

lncRNA DLEU2 modulates cell proliferation and invasion of non-small cell lung cancer by regulating miR-30c-5p/SOX9 axis
por: Zhou, Yongchun, et al.
Publicado: (2019)

miR-107 inhibited malignant biological behavior of non-small cell lung cancer cells by regulating the STK33/ERK signaling pathway in vivo and vitro
por: Wei, Xueqiang, et al.
Publicado: (2020)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
por: Friedlaender, Alex, et al.
Publicado: (2021)

Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review
por: Wang, Qian, et al.
Publicado: (2022)

The Novel Methylation Biomarker SCARA5 Sensitizes Cancer Cells to DNA Damage Chemotherapy Drugs in NSCLC
por: Peng, Qi, et al.
Publicado: (2021)

The Polymorphism and Expression of EGFL7 and miR-126 Are Associated With NSCLC Susceptibility
por: Liu, Weipeng, et al.
Publicado: (2022)

Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses
por: Zhang, Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kkqc5r7jkp049abt5naipmd82s